Beyond The Surface: Insights Into Psoriasis Pathophysiology and Therapy

Abstract

The autoimmune disease known as psoriasis affects 2-3 percent of all people worldwide while remaining as a continuous skin disorder. The clinical expressions from psoriasis adversely affect both physical health alongside mental wellness of patients. Pathogenesis arises via immune dysregulation that mostly affects keratinocyte proliferation through IL-23/Th17 axis activation. Genetic inheritances work together with environmental triggers as well as immune system responses to start and drive the development of diseases and progression. Medical professionals provide patients with mild psoriatic symptoms topical remedies yet systemic biologic drugs fight inflammatory cytokines in serious situations. A promising development emerges from JAK inhibitors and IL-23 antagonists which have become new therapeutic options. The study examines both the disease mechanism and medical approaches and new strategies for treating psoriasis.